Extended-Release niacin raises fasting glucose levels

March 28, 2012
Extended-Release niacin raises fasting glucose levels

(HealthDay) -- The combination of extended-release niacin (N) with ezetimibe plus simvastatin (E/S) to treat hyperlipidemia is associated with increased fasting glucose (FG) levels compared with E/S alone, but these cases tend to be transient and remit without intervention, according to research published in the April issue of Diabetes Care.

In an effort to determine whether extended-release niacin affected FG levels or the incidence of new-onset diabetes, John R. Guyton, M.D., of Duke University in Durham, N.C., and colleagues conducted a secondary analysis of data from 942 patients with hyperlipidemia treated for 64 weeks with either E/S or E/S plus extended-release niacin (E/S+N).

The researchers found that FG levels peaked by eight to 12 weeks and then declined even without use of antidiabetic therapies. At 64 weeks, the criteria for new onset diabetes was met by 3.5 percent of those taking E/S+N and 2.6 percent of those taking E/S (P = 0.66). The criteria for diabetes was transiently met by an additional 1.4 percent of those taking E/S+N versus 0.4 percent taking E/S, all of whom then remitted (P = 0.46). By 24 weeks, 25 of the 28 new diabetes diagnoses in the E/S+N group had occurred. In those with diabetes at baseline, antidiabetic treatment modification was undertaken by 13.9 percent of those taking E/S+N versus 11.6 percent taking E/S.

"In summary, combination E/S+N produced small initial increases in FG and new diagnoses of diabetes that dissipated over time, largely without the use of antidiabetic medication," the authors write.

The study was funded by Merck/Schering-Plough Pharmaceuticals; several authors disclosed to pharmaceutical companies, including Merck.

Explore further: FDA approves first diabetes-cholesterol combo pill

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

FDA approves first diabetes-cholesterol combo pill

October 7, 2011

(AP) -- The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience - and savings - to patients taking multiple pills.

Combo of diabetes, depression increases post-MI mortality

February 27, 2012

(HealthDay) -- Having both diabetes and depression significantly increases the risk of dying in the years following a heart attack, beyond the increased risk from either condition alone, according to a study published in ...

Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research ...

Recommended for you

Major fall in diabetes-related amputations since the 1990s

November 22, 2015

A major new study has found a significant reduction in diabetes-related amputations since the mid-1990s, credited to improvements in diabetes care over this period. The research is published in Diabetologia (the journal of ...

Blocking immune cell treats new type of age-related diabetes

November 18, 2015

Diabetes is often the result of obesity and poor diet choices, but for some older adults the disease might simply be a consequence of aging. New research has discovered that diabetes—or insulin resistance—in aged, lean ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.